Recent advancements in drug development for pulmonary tuberculosis

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a critical global health issue, infecting millions annually.
• Drug resistance, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, significantly complicates treatment with current first- and second-line anti-tuberculosis drugs (ATD).

Purpose of the Study:

• To review the limitations of existing TB treatment regimens.
• To discuss recent advancements in TB pharmacological management, including novel drug development and therapeutic strategies.
• To highlight innovative approaches for combating drug-resistant TB.

Main Methods:

• Literature review of current TB treatment guidelines and recent research.
• Analysis of emerging therapeutic options for drug-sensitive and drug-resistant TB.
• Discussion of challenges in TB management, such as adherence and evolving resistance patterns.

Main Results:

• Introduction of shorter 6-month regimens and all-oral treatment options (e.g., BPaLM regimen) for MDR/Rifampicin-resistant TB.
• Availability of longer 18-20-month regimens for complex resistance cases.
• Ongoing research focuses on new drug molecules, adjunct therapies, and faster diagnostics to improve efficacy and tolerability.

Conclusions:

• Recent advancements offer improved treatment outcomes for various forms of TB, including drug-resistant strains.
• A patient-centered approach is crucial for achieving equitable and sustainable global TB health outcomes.
• Continued research and innovation are essential to address the evolving threat of Mycobacterium tuberculosis.